Loading stock data…
$2.31-0.13 (-5.32%)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
Editas Medicine, Inc. in the Healthcare sector is trading at $2.44 with a market capitalization of $445M. Wall Street consensus targets $6.10 (10 analysts), implying a +150.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $4.33, remaining 8.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.89M↑ | $2.83M↓ | $24.74M↑ | $7.54M↑ | $3.58M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.89M↑ | -$25.00M↓ | -$14.02M↑ | -$24.55M↑ | -$25.46M |
| Net Income | -$18.23M↑ | -$24.98M↓ | -$5.62M↑ | -$25.12M↑ | -$53.23M |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead...